Agustín Lage Dávila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agustín Lage Dávila has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Nuris Ledón
Clinical Immunology Department, Center of Molecular Immunology, Havana 11600, Cuba
3 shared publications - Ana Laura Añé-Kourí
Clinical Research Direction, Center of Molecular Immunology, Havana, Cuba
2 shared publications - Carlos Herrera
Departamento de Medicina Intensiva. Hospital Universitario Arnaldo Milián Castro. Villa Clara. Cuba. Departamento de Medicina Intensiva. Hospital Universitario Manuel Fajardo. Villa Clara. Cuba
2 shared publications - César Fidel Sánchez Valdés
Departamento de Física y Matemáticas, Extensión Multidisciplinaria en Ciudad Universitaria, Instituto de Ingeniería y Tecnología, Universidad Autónoma de Ciudad Juárez, Ciudad Juárez 32310, Chihuahua, Mexico
2 shared publications - Danay Saavedra
Clinical Research Direction, Center of Molecular Immunology, Havana, Cuba
2 shared publications - Eligio E. Barreto Fiu
Departamento de Bioestadística. Universidad Médica de Villa Clara. Cuba
2 shared publications
Latest Publications
- 5 August 2024
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 4 (4) , 433-445
Assessment of non-classical lymphocyte populations in patients with advanced lung cancer treated with Biomodulina T following platinum-based chemotherapy
Aim: Currently, malignant diseases represent a health issue worldwide. Among these, lung cancer is of growing importance, due to its high incidence and mortality. Chemotherapy, one of the most frequently used treatments, has shown its ability to induce accelerated immunosenescence in classic and as well non-classic lymphocyte compartments, being less described in the latter. The immune restoration strategies have demonstrated their ability to reverse immunosenescence and exhaustion markers in conventional lymphocyte subpopulations after chemotherapy. However, the possible immunorestorative effect on non-classical lymphocytes has not been widely reported. The aim of this study was to evaluate the effect of chemotherapy and the administration of a thymic polypeptide factor on non-classical lymphocyte populations in patients with advanced lung cancer. Methods: Eighteen patients with advanced lung cancer, were evaluated at baseline before and after platinum-based chemotherapy (4–6 cycles). All patients could complete treatment with a thymic polypeptide factor [Biomodulina T (BT)] at the end of chemotherapy. Blood from patients was collected by venipuncture in heparinized tubes before and after chemotherapy and at the end of BT treatment to analyze the frequencies of non-classical immune subpopulations by flow cytometry. Results: Natural killer (NK), natural killer T cells (NKT), and double-positive T lymphocyte (DPT) proportions reached normal values in patients diagnosed with advanced lung cancer before receiving cytotoxic treatment. Chemotherapy did not induce modifications in the total percent of NK, NKT, and DPT populations in these patients. However, the administration of BT decreased DPTs and NK cells expressing the cluster of differentiation (CD)57 molecule, which is considered a marker of immunosenescence. Conclusions: These results suggest a lower influence of platinum-based chemotherapy on non-classical lymphocytes and the potential to generate a reconstitution of lymphocyte subpopulations in patients with advanced lung cancer by using the thymic factor BT, which reveals a new possibility for improving the response to cancer immunotherapies [Cuban Public Registry of Clinical Trial (RPCEC, https://rpcec.sld.cu/en/trials/RPCEC00000358-En) identifier: RPCEC00000358].
- 5 August 2024
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 4 (4) , 433-445
Assessment of non-classical lymphocyte populations in patients with advanced lung cancer treated with Biomodulina T following platinum-based chemotherapy
Aim: Currently, malignant diseases represent a health issue worldwide. Among these, lung cancer is of growing importance, due to its high incidence and mortality. Chemotherapy, one of the most frequently used treatments, has shown its ability to induce accelerated immunosenescence in classic and as well non-classic lymphocyte compartments, being less described in the latter. The immune restoration strategies have demonstrated their ability to reverse immunosenescence and exhaustion markers in conventional lymphocyte subpopulations after chemotherapy. However, the possible immunorestorative effect on non-classical lymphocytes has not been widely reported. The aim of this study was to evaluate the effect of chemotherapy and the administration of a thymic polypeptide factor on non-classical lymphocyte populations in patients with advanced lung cancer. Methods: Eighteen patients with advanced lung cancer, were evaluated at baseline before and after platinum-based chemotherapy (4–6 cycles). All patients could complete treatment with a thymic polypeptide factor [Biomodulina T (BT)] at the end of chemotherapy. Blood from patients was collected by venipuncture in heparinized tubes before and after chemotherapy and at the end of BT treatment to analyze the frequencies of non-classical immune subpopulations by flow cytometry. Results: Natural killer (NK), natural killer T cells (NKT), and double-positive T lymphocyte (DPT) proportions reached normal values in patients diagnosed with advanced lung cancer before receiving cytotoxic treatment. Chemotherapy did not induce modifications in the total percent of NK, NKT, and DPT populations in these patients. However, the administration of BT decreased DPTs and NK cells expressing the cluster of differentiation (CD)57 molecule, which is considered a marker of immunosenescence. Conclusions: These results suggest a lower influence of platinum-based chemotherapy on non-classical lymphocytes and the potential to generate a reconstitution of lymphocyte subpopulations in patients with advanced lung cancer by using the thymic factor BT, which reveals a new possibility for improving the response to cancer immunotherapies [Cuban Public Registry of Clinical Trial (RPCEC, https://rpcec.sld.cu/en/trials/RPCEC00000358-En) identifier: RPCEC00000358].
- Open Access
Resolved vs. uncontrolled inflammation: a mathematical model to decipher the role of innate immunity
Neutrophils and macrophages related processes have been described as relevant during the inflammation resolution after an acute damage. Nevertheless, understanding the impact of both cells and the processes in which they are involved is still an open debate. Specifically, several studies have been focused on elucidate their impact in the dynamic outcome of resolution vs uncontrolled response. In this work, we develop a mathematical model that describe the dynamic of the innate immune response after an acute damage. Our model includes all the described processes that mediate this response, including the regulatory mechanisms carried out by type-2 macrophages (M2). Additionally, we estimate the resolution indices to quantify the efficiency of resolution mechanisms by controlling the initial expansion of Neutrophils and/or the subsequent contraction kinetics of the cell response. We predict that the processes of cells influx into the inflamed site, Neutrophil apoptosis and type-1 macrophage (M1)-mediated efferocytosis, are the ones that have an impact on the final outcome, but interfering in different resolution indices. In particular, we predict that the partial reduction of Neutrophil influx and the increase of M1-mediated efferocytosis rate are the best strategies to control the Neutrophil initial expansion. On the other hand, the partial reduction of M1 cells influx or the increase of Neutrophil apoptosis rate are predicted as good strategies to accelerate the Neutrophils decay during the contraction phase of the response.
Open AccessResolved vs. uncontrolled inflammation: a mathematical model to decipher the role of innate immunity
Neutrophils and macrophages related processes have been described as relevant during the inflammation resolution after an acute damage. Nevertheless, understanding the impact of both cells and the processes in which they are involved is still an open debate. Specifically, several studies have been focused on elucidate their impact in the dynamic outcome of resolution vs uncontrolled response. In this work, we develop a mathematical model that describe the dynamic of the innate immune response after an acute damage. Our model includes all the described processes that mediate this response, including the regulatory mechanisms carried out by type-2 macrophages (M2). Additionally, we estimate the resolution indices to quantify the efficiency of resolution mechanisms by controlling the initial expansion of Neutrophils and/or the subsequent contraction kinetics of the cell response. We predict that the processes of cells influx into the inflamed site, Neutrophil apoptosis and type-1 macrophage (M1)-mediated efferocytosis, are the ones that have an impact on the final outcome, but interfering in different resolution indices. In particular, we predict that the partial reduction of Neutrophil influx and the increase of M1-mediated efferocytosis rate are the best strategies to control the Neutrophil initial expansion. On the other hand, the partial reduction of M1 cells influx or the increase of Neutrophil apoptosis rate are predicted as good strategies to accelerate the Neutrophils decay during the contraction phase of the response.
- 12 October 2023
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 35 (11) , 2839-2842
Immunosenescence and inflammatory markers in Cuban centenarians: implications for survival
Centenarians are the best example of successful aging in humans. This work aimed to understand if immune status is associated with survival in Cuban centenarians. In a previous study, our group enrolled 43 centenarians and evaluated their immune status and functional capacity. 41 out of 43 recruited centenarians received follow-up phone calls, during a period of 2 years. Absolute CD4 + T cell count was higher among survivors, while the frequency of CD8 + CCR7-CD45RA + , CD8 + CD45RA + CD28-, and CD4 + CD28- T cells was higher among non-survivors. We also found that higher frequencies of terminally differentiated T cells were related to a higher risk of death, while centenarians with higher frequencies of T cells were more likely to survive. Surprisingly, neither serum inflammatory markers nor frailty/dependency was associated with survival. Our preliminary study suggests that immuno-senescence markers, but not inflammaging or functional capacity, are associated with survival beyond 100 years in a small group of Cuban centenarians.
- 12 October 2023
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 35 (11) , 2839-2842
Immunosenescence and inflammatory markers in Cuban centenarians: implications for survival
Centenarians are the best example of successful aging in humans. This work aimed to understand if immune status is associated with survival in Cuban centenarians. In a previous study, our group enrolled 43 centenarians and evaluated their immune status and functional capacity. 41 out of 43 recruited centenarians received follow-up phone calls, during a period of 2 years. Absolute CD4 + T cell count was higher among survivors, while the frequency of CD8 + CCR7-CD45RA + , CD8 + CD45RA + CD28-, and CD4 + CD28- T cells was higher among non-survivors. We also found that higher frequencies of terminally differentiated T cells were related to a higher risk of death, while centenarians with higher frequencies of T cells were more likely to survive. Surprisingly, neither serum inflammatory markers nor frailty/dependency was associated with survival. Our preliminary study suggests that immuno-senescence markers, but not inflammaging or functional capacity, are associated with survival beyond 100 years in a small group of Cuban centenarians.
- Open Access
- 10 August 2021
- Published by Universidad Autonoma de Chile in International Journal of Medical and Surgical Sciences
- Vol. 8 (3) , 1-15
Variables associated with severity in COVID-19 patients
In COVID-19, a percentage of patients develop severe disease, with high mortality, since has been necessary to study its characteristics to stop the progression of the disease. A retrospective study was carried out in a cohort of 150 adult patients attended at Manuel Fajardo Hospital in Villa Clara, Cuba, from March to June 2020. Demographic, clinical, laboratory, gasometric and radiological variables measured at hospital admission were analyzed, defining two groups of patients according to clinical evolution: severe and non-severe. For the comparison of the groups a bivariate analysis was performed, with the objective of determining those variables with a significant association to severity. Of the total number of patients, 26 (17.3%) evolved to severity and 124 (83.7%) evolved satisfactorily. Severe patients were characterized by advanced age (mean: 83 years) and comorbidities; the most significant being hypertension, diabetes mellitus, heart disease, chronic kidney disease and cancer (p< 0.0001). Polypnea and diarrhea were the clinical manifestations with the highest association with severity (p<0.0001), followed by fever (p=0.0157). The quick SOFA prognostic scale proved to be a useful instrument to evaluate patients at admission. Laboratory variables: neutrophils, lymphocytes, neutrophil/lymphocyte ratio, hemoglobin and lactate dehydrogenase were the most associated with severity (p<0.0001). Leukocytes, lactate, D-dimer, C-reactive protein, glycemia and calcium also showed significant results (p<0.05). Of the gasometric variables, arterial oxygen pressure and saturation were the most significantly associated with severity; as well as the presence of pulmonary infiltrates or consolidation in the chest X-ray (p<0.0001). The study allowed us to identify variables at hospital admission associated with progression to severe forms of the disease.
- 10 August 2021
- Published by Universidad Autonoma de Chile in International Journal of Medical and Surgical Sciences
- Vol. 8 (3) , 1-15
Open AccessVariables associated with severity in COVID-19 patients
In COVID-19, a percentage of patients develop severe disease, with high mortality, since has been necessary to study its characteristics to stop the progression of the disease. A retrospective study was carried out in a cohort of 150 adult patients attended at Manuel Fajardo Hospital in Villa Clara, Cuba, from March to June 2020. Demographic, clinical, laboratory, gasometric and radiological variables measured at hospital admission were analyzed, defining two groups of patients according to clinical evolution: severe and non-severe. For the comparison of the groups a bivariate analysis was performed, with the objective of determining those variables with a significant association to severity. Of the total number of patients, 26 (17.3%) evolved to severity and 124 (83.7%) evolved satisfactorily. Severe patients were characterized by advanced age (mean: 83 years) and comorbidities; the most significant being hypertension, diabetes mellitus, heart disease, chronic kidney disease and cancer (p< 0.0001). Polypnea and diarrhea were the clinical manifestations with the highest association with severity (p<0.0001), followed by fever (p=0.0157). The quick SOFA prognostic scale proved to be a useful instrument to evaluate patients at admission. Laboratory variables: neutrophils, lymphocytes, neutrophil/lymphocyte ratio, hemoglobin and lactate dehydrogenase were the most associated with severity (p<0.0001). Leukocytes, lactate, D-dimer, C-reactive protein, glycemia and calcium also showed significant results (p<0.05). Of the gasometric variables, arterial oxygen pressure and saturation were the most significantly associated with severity; as well as the presence of pulmonary infiltrates or consolidation in the chest X-ray (p<0.0001). The study allowed us to identify variables at hospital admission associated with progression to severe forms of the disease.
- Open Access
- 6 April 2021
- Published by Universidad Autonoma de Chile in European Journal of Health Research
- Vol. 7 (2) , 1-19
Nomograma de predicción para la estratificación del riesgo en pacientes con COVID-19
COVID-19 can progress to severe forms of the disease with high mortality, so it has been necessary to identify predictive factors that allow stratifying the risk in patients. A retrospective analytical study was carried out in a cohort of 150 patients from Manuel Fajardo Hospital in Villa Clara, Cuba, from March to June 2020. With the information obtained, a severity prognostic index was constructed by means of a multivariate binary logistic regression model, in which the probability of the patient evolving towards severity was expressed as a function of the set of variables that were identified as predictors of the health event of interest. R software version 4.0.2 (22-06-2020) was used to summarize the data and apply the hypothesis tests. With the final results, a prognostic index was elaborated through a mathematical equation on which the model is based. A prediction nomogram was constructed to facilitate its interpretation, which constituted the main output of this study. The variables with the highest predictive power, which definitely remained in the model and with the nomogram was constructed were: age (p=0.049), arterial hypertension (p=0.013), neutrophil/lymphocyte ratio (p=0.004), lactate dehydrogenase (p=0.039) and arterial oxygen saturation (p=0.044). The Hosmer-Lemeshow test statistic result was p= 0.976 and the discriminatory capacity given by the area under the ROC curve (receiver operating characteristic curve) was equal to 0.988 (AUC: 0.9882, 95% CI: 0.9756-1). The optimal cut-off point was 0.099. We conclude that our nomogram is a very useful tool for the early identification of patients at risk of progressing to severe forms of COVID-19. In this way, it facilitates better stratification and the adequacy of timely treatment, capable of slowing disease progression
- 6 April 2021
- Published by Universidad Autonoma de Chile in European Journal of Health Research
- Vol. 7 (2) , 1-19
Open AccessNomograma de predicción para la estratificación del riesgo en pacientes con COVID-19
COVID-19 can progress to severe forms of the disease with high mortality, so it has been necessary to identify predictive factors that allow stratifying the risk in patients. A retrospective analytical study was carried out in a cohort of 150 patients from Manuel Fajardo Hospital in Villa Clara, Cuba, from March to June 2020. With the information obtained, a severity prognostic index was constructed by means of a multivariate binary logistic regression model, in which the probability of the patient evolving towards severity was expressed as a function of the set of variables that were identified as predictors of the health event of interest. R software version 4.0.2 (22-06-2020) was used to summarize the data and apply the hypothesis tests. With the final results, a prognostic index was elaborated through a mathematical equation on which the model is based. A prediction nomogram was constructed to facilitate its interpretation, which constituted the main output of this study. The variables with the highest predictive power, which definitely remained in the model and with the nomogram was constructed were: age (p=0.049), arterial hypertension (p=0.013), neutrophil/lymphocyte ratio (p=0.004), lactate dehydrogenase (p=0.039) and arterial oxygen saturation (p=0.044). The Hosmer-Lemeshow test statistic result was p= 0.976 and the discriminatory capacity given by the area under the ROC curve (receiver operating characteristic curve) was equal to 0.988 (AUC: 0.9882, 95% CI: 0.9756-1). The optimal cut-off point was 0.099. We conclude that our nomogram is a very useful tool for the early identification of patients at risk of progressing to severe forms of COVID-19. In this way, it facilitates better stratification and the adequacy of timely treatment, capable of slowing disease progression
- 18 February 2014
- Published by Wiley in Pediatrics International
- Vol. 56 (1) , 43-46
Brain tumor response to nimotuzumab treatment evaluated on magnetic resonance imaging
Nimotuzumab, a humanized monoclonal antibody anti-epidermal growth factor receptor, has been shown to improve survival and quality of life in patients with pediatric malignant brain tumor. It is necessary, however, to increase the objective response criteria to define the optimal therapeutic schedule. The aim of this study was to obtain magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) quantitative information related to dimensions and morphology, molecular mobility and metabolic activity of the lesion and surroundings in order to evaluate any changes through time. Fourteen pediatric patients treated with nimotuzumab were evaluated on MRI and MRS for >2 years. Each patient was their own control. The MRI/MRS pulse sequence parameters were standardized to ensure experimental reproducibility. A total of 71.4% of patients had stable disease; 21.4% had objective response and 7.1% had progression of disease during the >2 year evaluation period. MRI/MRS data with clinical information provide a clearer picture of treatment response and confirm once again that nimotuzumab is effective in the treatment of pediatric brain tumor. These imaging procedures can be a useful tool for the clinical evaluation of study protocol in clinical practice.
- 18 February 2014
- Published by Wiley in Pediatrics International
- Vol. 56 (1) , 43-46
Brain tumor response to nimotuzumab treatment evaluated on magnetic resonance imaging
Nimotuzumab, a humanized monoclonal antibody anti-epidermal growth factor receptor, has been shown to improve survival and quality of life in patients with pediatric malignant brain tumor. It is necessary, however, to increase the objective response criteria to define the optimal therapeutic schedule. The aim of this study was to obtain magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) quantitative information related to dimensions and morphology, molecular mobility and metabolic activity of the lesion and surroundings in order to evaluate any changes through time. Fourteen pediatric patients treated with nimotuzumab were evaluated on MRI and MRS for >2 years. Each patient was their own control. The MRI/MRS pulse sequence parameters were standardized to ensure experimental reproducibility. A total of 71.4% of patients had stable disease; 21.4% had objective response and 7.1% had progression of disease during the >2 year evaluation period. MRI/MRS data with clinical information provide a clearer picture of treatment response and confirm once again that nimotuzumab is effective in the treatment of pediatric brain tumor. These imaging procedures can be a useful tool for the clinical evaluation of study protocol in clinical practice.